Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Clinical trial NCT03142334 · COMPLETED
Trial details
- NCT number
- NCT03142334
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-09
- Primary completion
- 2020-12-14
- Enrollment
- 994
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.